EMA Reviews Lundbeck’s Deanxit After Reports of Serious Side Effects

The European Medicines Agency said its risk-monitoring committee had begun reviewing Lundbeck’s depression and anxiety medicine Deanxit following reports of serious neurological and psychiatric side effects.